Bristol Myers, SystImmune drug cuts breast cancer progression risk in study

Oct 23 (Reuters) Bristol Myers Squibb and partner SystImmune said ​on Friday their ‌experimental breast cancer treatment slowed disease progression compared to standard chemotherapy in ‌a ​late-stage study. The ⁠drug, izalontamab brengitecan, ⁠reduced the risk of disease worsening or death by 59% ​in patients with advanced hormone-receptor-positive, HER2-negative ⁠breast cancer, ⁠who had failed ​at least one prior ​line of chemotherapy. Patients treated with ‌the drug lived for an average of 8.2 months ⁠without their cancer growing, compared to four months for ⁠those ‌on standard chemotherapy. The ⁠full results will ​be ‌presented at the ​European Society ⁠for Medical Oncology congress in Madrid. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi ​Majumdar)